

Notice from the Executive Officer: Funding of Glatect (glatiramer acetate) under the Ontario Drug Benefit Program

September 20, 2018

Effective **September 27, 2018**, Glatect (glatiramer acetate) will be funded under the Ontario Drug Benefit (ODB) Program for eligible ODB recipients.

Glatect will be listed on the ODB Formulary/Comparative Drug Index (Formulary) as a Limited Use (LU) benefit for the following indications:

As monotherapy for the treatment of patients with relapsing remitting multiple sclerosis (RRMS) meeting ALL the following criteria:

- Recent neurological examination consistent with the diagnosis of RRMS; AND
- Lesions typical of multiple sclerosis on brain magnetic resonance imaging (MRI); AND
- Experienced at least 2 clinical attacks in their lifetime with one attack occurring within the prior year; AND
- EDSS score less than or equal to 6.0 prior to start of treatment; AND
- Prescribed by a neurologist who is experienced in the treatment of Multiple Sclerosis.

Authorization period: 1 year

As monotherapy for the treatment of patients who have experienced a single demyelinating event/ Clinically Isolated Syndrome (CIS) meeting ALL the following criteria:

- CIS occurred within the prior 12 months; AND
- Recent neurological examination; AND
- Lesions typical of CIS confirmed on brain magnetic resonance imaging (MRI); AND
- EDSS score less than or equal to 6.0 prior to start of treatment; AND
- Prescribed by a neurologist who is experienced in the treatment of Multiple Sclerosis

Authorization period: 1 year

Ministry of Health and Long-Term Care Ontario Public Drug Programs

Renewal of therapy for patients diagnosed with relapsing remitting multiple sclerosis (RRMS) or a single demyelinating event /Clinically Isolated Syndrome (CIS) who meet ALL the following criteria:

- Used as monotherapy for the treatment of RRMS or CIS; AND
- EDSS score less than or equal to 6.0; AND
- Disease activity is stabilized as determined by a neurological exam and the number of clinical relapses experienced while on treatment; AND
- Prescribed by a neurologist experienced in the treatment of Multiple Sclerosis (MS) OR a prescriber in consultation with a neurologist overseeing the patient's MS.

Authorization period: 1 year

Details of the LU criteria will also be posted in the September 2018 Formulary update which can be found on the ministry's website at:

http://www.health.gov.on.ca/en/pro/programs/drugs/odbf_eformulary.aspx

To further inform healthcare providers and patients, we have also included a Frequently Asked Questions (FAQs) document for reference purposes.

Additional Information:

For pharmacies:

Please call ODB Pharmacy Help Desk at: 1-800-668-6641

For all other Health Care Providers and the Public:

Please call ServiceOntario, Infoline at 1-866-532-3161 TTY 1-800-387-5559. In Toronto, TTY 416-327-4282.